

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock code: 1696)

**INTERIM RESULTS ANNOUNCEMENT
FOR THE SIX MONTHS ENDED JUNE 30, 2021**

FINANCIAL HIGHLIGHTS

For the six months ended June 30, 2021:

- Revenue was US\$125.3 million, increased by 74.7% as compared to that for the six months ended June 30, 2020.
- Profit for the period attributable to owners of the parent was US\$16.4 million, increased by 197.6% as compared to that for the six months ended June 30, 2020.
- Net cash flows from operating activities for the period was US\$20.8 million, as compared to US\$0.1 million used in operating activities for the corresponding period in 2020.

INTERIM DIVIDEND

- The Board resolved not to declare any interim dividend for the six months ended June 30, 2021.

RESULTS HIGHLIGHTS

The board of directors (the “**Board**”) of Sisram Medical Ltd (the “**Company**” or “**Sisram**”) is pleased to announce the unaudited consolidated results of the Company and its subsidiaries (collectively referred to as the “**Group**” or “**we**”) for the six months ended June 30, 2021 (the “**Reporting Period**”), together with the comparative figures for the corresponding period in 2020. The results have been prepared in accordance with International Financial Reporting Standards (the “**IFRSs**”).

* *For identification purpose only*

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

		Six months ended June 30,	
	Notes	2021	2020
		<i>US\$'000</i>	<i>US\$'000</i>
		<i>(Unaudited)</i>	<i>(Unaudited)</i>
REVENUE	4	125,293	71,736
Cost of sales		<u>(53,815)</u>	<u>(31,834)</u>
Gross profit		71,478	39,902
Other income and gains		316	988
Selling and distribution expenses		(30,032)	(19,834)
Administrative expenses		(9,280)	(8,088)
Research and development expenses		(8,050)	(4,955)
Other expenses		(3,104)	(1,271)
Finance costs		(921)	(348)
Share of profits and losses of associates		<u>(270)</u>	<u>–</u>
PROFIT BEFORE TAX	5	20,137	6,394
Income tax expense	6	<u>(2,776)</u>	<u>(656)</u>
PROFIT FOR THE PERIOD		<u><u>17,361</u></u>	<u><u>5,738</u></u>
Attributable to:			
Owners of the parent		16,379	5,504
Non-controlling interests		<u>982</u>	<u>234</u>
		<u><u>17,361</u></u>	<u><u>5,738</u></u>
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	8		
Basic and diluted			
For profit for the period (US cents)		<u><u>3.70</u></u>	<u><u>1.24</u></u>

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Six months ended June 30,	
	2021	2020
	<i>US\$'000</i>	<i>US\$'000</i>
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
PROFIT FOR THE PERIOD	<u>17,361</u>	<u>5,738</u>
OTHER COMPREHENSIVE INCOME		
Other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods:		
Cash flow hedges:		
Effective portion of changes in fair value of hedging instruments arising during the period	(96)	160
Reclassification adjustments for loss included in the consolidated statement of profit or loss	<u>(7)</u>	<u>—</u>
	(103)	160
Exchange differences:		
Exchange differences on translation of foreign operations	(1,211)	(306)
Net other comprehensive loss that may be reclassified to profit or loss in subsequent periods	<u>(1,314)</u>	<u>(146)</u>
Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods:		
Actuarial reserve relating to a defined benefit plan	<u>—</u>	<u>(50)</u>
Net other comprehensive loss that will not be reclassified to profit or loss in subsequent periods	<u>—</u>	<u>(50)</u>
OTHER COMPREHENSIVE LOSS FOR THE PERIOD, NET OF TAX	<u>(1,314)</u>	<u>(196)</u>
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	<u>16,047</u>	<u>5,542</u>
Attributable to:		
Owners of the parent	15,065	5,308
Non-controlling interests	<u>982</u>	<u>234</u>
	<u>16,047</u>	<u>5,542</u>

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

		As at June 30, 2021	As at December 31, 2020
	Notes	<i>US\$'000</i> <i>(Unaudited)</i>	<i>US\$'000</i> <i>(Audited)</i>
NON-CURRENT ASSETS			
Property, plant and equipment	9	13,764	12,813
Right-of-use assets		32,263	33,348
Goodwill		111,183	111,183
Other intangible assets		49,487	53,281
Investments in associates		853	173
Deferred tax assets		5,809	5,047
Trade receivables	10	10,899	10,616
Other non-current assets		224	195
		<hr/>	<hr/>
Total non-current assets		224,482	226,656
CURRENT ASSETS			
Inventories		40,424	37,191
Trade receivables	10	56,168	46,501
Prepayments, other receivables and other assets		4,861	3,955
Tax recoverable		–	976
Derivative financial instruments		372	–
Cash and bank balances		129,430	116,527
		<hr/>	<hr/>
Total current assets		231,255	205,150
CURRENT LIABILITIES			
Contract liabilities		11,969	8,178
Trade payables	11	13,371	9,444
Other payables and accruals		38,008	32,357
Derivative financial instruments		–	479
Interest-bearing bank and other borrowings		348	1,518
Lease liabilities		3,243	2,817
Tax payable		1,406	–
		<hr/>	<hr/>
Total current liabilities		68,345	54,793
NET CURRENT ASSETS		<hr/>	<hr/>
		162,910	150,357
TOTAL ASSETS LESS CURRENT LIABILITIES		<hr/>	<hr/>
		387,392	377,013

	As at June 30, 2021	As at December 31, 2020
Notes	<i>US\$'000</i> <i>(Unaudited)</i>	<i>US\$'000</i> <i>(Audited)</i>
NON-CURRENT LIABILITIES		
Contract liabilities	398	218
Interest-bearing bank and other borrowings	58	180
Lease liabilities	30,873	32,548
Deferred tax liabilities	9,659	9,910
Other long-term liabilities	2,229	2,268
	<hr/>	<hr/>
Total non-current liabilities	43,217	45,124
	<hr/>	<hr/>
NET ASSETS	344,175	331,889
	<hr/> <hr/>	<hr/> <hr/>
EQUITY		
Equity attributable to owners of the parent		
Share capital	1,254	1,254
Reserves	342,921	330,635
	<hr/>	<hr/>
Total equity	344,175	331,889
	<hr/> <hr/>	<hr/> <hr/>

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. BASIS OF PREPARATION

The unaudited interim condensed consolidated financial information for the six months ended June 30, 2021 (the “**Reporting Period**”) has been prepared in accordance with IAS 34 *Interim Financial Reporting*. The unaudited interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group’s consolidated financial statements as at December 31, 2020.

2. CHANGES IN ACCOUNTING POLICIES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2020, except for the adoption of the following revised International Financial Reporting Standards (“**IFRSs**”) for the first time for the current period’s financial information.

Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16	<i>Interest Rate Benchmark Reform – Phase 2</i>
Amendments to IFRS 16	<i>Covid-19-Related Rent Concessions</i>
	<i>beyond 30 June 2021 (early adopted)</i>

The nature and impact of the revised IFRSs are described below:

- (a) Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 address issues not dealt with in the previous amendments which affect financial reporting when an existing interest rate benchmark is replaced with an alternative risk-free rate (“**RFR**”). The phase 2 amendments provide a practical expedient to allow the effective interest rate to be updated without adjusting the carrying amount of financial assets and liabilities when accounting for changes in the basis for determining the contractual cash flows of financial assets and liabilities, if the change is a direct consequence of the interest rate benchmark reform and the new basis for determining the contractual cash flows is economically equivalent to the previous basis immediately preceding the change. In addition, the amendments permit changes required by the interest rate benchmark reform to be made to hedge designations and hedge documentation without the hedging relationship being discontinued. Any gains or losses that could arise on transition are dealt with through the normal requirement of IFRS 9 and IAS 39 to measure and recognize hedge ineffectiveness. The amendments also provide a temporary relief to entities from having to meet the separately identifiable requirement when an RFR is designated as a risk component. The relief allows an entity, upon designation of the hedge, to assume that the separately identifiable requirement is met, provided the entity reasonably expects the RFR risk component to become separately identifiable within the next 24 months. Furthermore, the amendments require an entity to disclose additional information to enable users of financial statements to understand the effect of interest rate benchmark reform on an entity’s financial instruments and risk management strategy. The amendments are effective for annual periods beginning on or after January 1, 2021 and shall be applied retrospectively, but entities are not required to restate the comparative information.

The Group did not have certain interest-bearing bank borrowings based on the Interbank Offered Rates as at June 30, 2021. The amendments are not expected to have any significant impact on the Group’s financial statements.

- (b) Amendment to IFRS 16 issued in March 2021 extends the availability of the practical expedient for lessees to elect not to apply lease modification accounting for rent concessions arising as a direct consequence of the covid-19 pandemic by 12 months. Accordingly, the practical expedient applies to rent concessions for which any reduction in lease payments affects only payments originally due on or before 30 June 2022, provided the other conditions for applying the practical expedient are met. The amendment is effective retrospectively for annual periods beginning on or after April 1, 2021 with any cumulative effect of initially applying the amendment recognized as an adjustment to the opening balance of retained profits at the beginning of the current accounting period. Earlier application is permitted.

The amendments did not have any significant impact on the financial position and performance of the Group for the period ended June 30, 2021.

3. OPERATING SEGMENT INFORMATION

For management purposes, the Group's operating activities are related to a single operating segment, which is the design, development, manufacture and sale of energy-based aesthetic medical and minimally invasive treatment systems, non-EBD devices and cosmeceuticals. Therefore, no analysis by operating segment is presented.

4. REVENUE

An analysis of revenue is as follows:

	For the six months ended June 30	
	2021	2020
	<i>US\$'000</i>	<i>US\$'000</i>
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
Revenue from contracts with customers		
Sale of goods	118,050	67,284
Services provided	7,243	4,452
	<u>125,293</u>	<u>71,736</u>

Disaggregated revenue information for revenue from contracts with customers

Segments

	For the six months ended June 30	
	2021	2020
	<i>US\$'000</i>	<i>US\$'000</i>
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
Types of goods or services		
Sale of goods	118,050	67,284
Services provided	7,243	4,452
	<u>125,293</u>	<u>71,736</u>

Geographical markets

Europe	23,698	16,367
North America	49,147	22,848
Asia Pacific	33,744	21,779
Latin America	6,068	3,161
Middle East and Africa	12,636	7,581
	<u>125,293</u>	<u>71,736</u>

	For the six months ended June 30	
	2021	2020
	<i>US\$'000</i>	<i>US\$'000</i>
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
Timing of revenue recognition		
Goods transferred at a point in time	118,050	67,284
Services transferred over time	7,243	4,452
	<u>125,293</u>	<u>71,736</u>

5. PROFIT BEFORE TAX

The Group's profit before tax from continuing operations is arrived at after charging/(crediting):

	For the six months ended June 30	
	2021	2020
	US\$'000	US\$'000
	(Unaudited)	(Unaudited)
Cost of inventories sold	35,727	20,508
Cost of services and others	18,088	11,326
	<u>53,815</u>	<u>31,834</u>
Research and development costs:		
Current year expenditure	8,050	4,955
Depreciation of property, plant and equipment	1,119	960
Depreciation of right-of-use assets	1,708	1,490
Amortization of other intangible assets	3,795	2,675
Provision for impairment of inventories	2,148	303
Provision for impairment of trade receivables	1,715	716
Foreign exchange differences, net	(759)	252

6. INCOME TAX

The Israeli corporate tax rates applicable to the Company were 23% for the Reporting Period (2020: 23%). Each entity in the group is taxable based on its standalone results as measured by the local tax system.

No income tax has been provided for the Company itself as there was no assessable profit earned by the Company for the Reporting Period. Taxes on taxable income assessable elsewhere have been calculated at the rates of tax prevailing in the countries in which the Group operates.

Nova Medical Israel Ltd. ("**Nova**") is taxed based upon the tax law in Israel, the country of residence. Income was taxed at corporate income tax rate of 23% for the Reporting Period (2020: 23%).

Alma Lasers Ltd. ("**Alma**"), the major operating subsidiary of the Company, was granted the status of "Preferred Enterprise" under the Law for the Encouragement of Capital Investments, 1959 (as amended in 2011, the "**2011 Amendment of the Investment Law**") and therefore enjoyed a preferential corporate tax rate of 16% during the period.

In December 2016, the Israeli Knesset passed Amendment 73 to the Investment Law, which included a number of changes to the Investments Law regime. Certain changes were scheduled to come into effect beginning January 1, 2017, provided that regulations are promulgated by the Finance Ministry to implement the "Nexus Principles" based on The Organisation for Economic Co-operation and Development's guidelines recently published as part of the Base Erosion and Profit Shifting (BEPS) project. The regulations were approved in May 2017 and accordingly, have come into effect.

Applicable benefits under the new regime include:

Introduction of a benefit regime for "Preferred Technology Enterprises", granting a 12% tax rate in central Israel and a 7.5% tax rate in special areas – on income deriving from Intellectual Property, subject to a number of conditions being fulfilled, including a minimal amount or ratio of annual research and development ("**R&D**") expenditure and R&D employees, as well as having at least 25% of annual income derived from exports. Technological Preferred Enterprise is defined as an enterprise which meets the aforementioned conditions and for which total consolidated revenues of its parent company and all subsidiaries are less than NIS10 billion. In cases where the parent company and all subsidiaries have more than NIS10 billion of consolidated revenues, the tax rate will be 6% in all Israel regions.

A Special Preferred Technological Enterprise (“**SPTE**”) – where the parent company’s total revenues are more than NIS10 billion in the tax year, its preferred income will be subject to a tax rate of 6%, regardless of the geographical location of the enterprise. On December 4, 2018, the Company received a ruling from the Israeli Income Tax Authority, which grants the Company the SPTE status, in accordance with the criteria in the law mentioned above and the conditions mentioned in the ruling, effective from January 1, 2017.

The following applies to SPTE:

- A 6% capital gains tax rate on the sale of a preferred intangible asset to a foreign affiliated enterprise, in accordance with the criteria mentioned in the law.
- A withholding tax rate of 20% for the dividends paid from a Preferred Technology Enterprise’s income (with an exemption from such withholding tax applying to dividends paid to an Israeli company). Such rate may be reduced to 4% on the dividends paid to a foreign resident company, subject to certain conditions regarding the percentage of foreign ownership of the distributing entity.

As of June 30, 2021, Alma enjoyed a preferential effective tax rate of 6%, for being a SPTE for the period ended June 30, 2021 (2020: 6%).

The U.S. Tax Cuts and Jobs Act of 2017 (“**TCJA**”) was approved by the U.S. Congress on December 20, 2017 and signed into law by the U.S. President Donald J. Trump on December 22, 2017. This legislation has made complex and significant changes to the U.S. Internal Revenue Code. Such changes include a reduction in the corporate tax rate and limitations on certain corporate deductions and credits, among other changes. The changes include, but are not limited to:

Rate reduction

The US is subject to various state income taxes of which the rates vary by state.

The TCJA reduces the U.S. federal corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017. In addition, the TCJA has made certain changes to the depreciation rules and implemented new limits on the deductibility of certain expenses and deduction.

The income of Alma Lasers GmbH, a subsidiary incorporated in Germany, is taxed based upon the tax law in Germany, the country of residence. Income was taxed at a flat corporate income tax rate of 15.825% during the Reporting Period and was also subject to additional trade income taxes of 16.345% as applicable.

The income of Alma Lasers AT GmbH, a subsidiary incorporated in Austria, is taxed based upon the tax law in Austria, the country of residence. Income was taxed at a flat corporate income tax rate of 25% during the Reporting Period and was also subject to additional trade income taxes as applicable.

The income of Alma Medical Private Limited, a subsidiary incorporated in India, is taxed based upon the tax law in India, the country of residence. Income was taxed at a corporate income tax rate of 25% and 4% Surcharge bringing it to 26% during the Reporting Period (which was not a flat rate but included many deductions/exemptions/rebates as per the Income Tax Act 1961) and the Company was also subject to withholding taxes as per the provisions of the said Income Tax Act 1961.

The income of Alma Medical HK Limited, a subsidiary incorporated in Hong Kong, is taxed at the rate of 16.5% on its estimated assessable profits arising in Hong Kong.

The income of Alma Medical Australia Pty Ltd, a subsidiary incorporated in Australia, is taxed at the rate of 30%.

The income of Alma Korea Limited, a subsidiary incorporated in Korea, is taxed at the rate of 17%.

	For the six months ended June 30	
	2021 <i>US\$'000</i> <i>(Unaudited)</i>	2020 <i>US\$'000</i> <i>(Unaudited)</i>
Current	3,789	1,054
Deferred	(1,013)	(398)
	<u>2,776</u>	<u>656</u>
Total tax charge for the period	<u>2,776</u>	<u>656</u>

7. DIVIDENDS

The board of directors resolved not to declare any interim dividend for the Reporting Period. (six months ended June 30, 2020: Nil).

On March 18, 2021, the board of directors resolved to declare a final dividend of HK\$0.07 (inclusive of tax, equivalent to approximately US\$0.01) per share for the year ended December 31, 2020. (for the year ended December 31, 2019: HK\$0.11). No dividends were paid during the Reporting Period (six months ended June 30, 2020: Nil).

8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amounts is based on the profit for the six months ended June 30, 2021 and 2020 attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 442,155,600 (six months ended June 30, 2020: 442,155,600) in issue during the period.

The calculation of basic and diluted earnings per share are based on:

	2021 <i>US\$'000</i> <i>(Unaudited)</i>	2020 <i>US\$'000</i> <i>(Audited)</i>
Earnings		
Profit attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation	<u>16,379</u>	<u>5,504</u>
	Number of shares	
	2021	2020
Shares		
Weighted average number of ordinary shares in issue during the period used in the basic earnings per share calculation	<u>442,155,600</u>	<u>442,155,600</u>

No adjustment has been made to the basic earnings per share presented for the six months ended June 30, 2020 and 2021 as the Group had no potentially dilutive ordinary shares in issue during those periods.

9. PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2021, the Group acquired assets at a cost of US\$2,080,000 (six months ended 30 June 2020: US\$6,256,000).

During the six months ended 30 June 2021, depreciation for property, plant and equipment was US\$1,119,000 (six months ended 30 June 2020: US\$960,000).

During the six months ended 30 June 2021, disposal of property, plant and equipment was nil (six months ended 30 June 2020: US\$48,000).

10. TRADE RECEIVABLES

	June 30, 2021	December 31, 2020
	<i>US\$'000</i>	<i>US\$'000</i>
	<i>(Unaudited)</i>	<i>(Audited)</i>
Trade receivables	70,080	58,787
Current	59,181	48,087
Non-current	10,899	10,700
Impairment	(3,013)	(1,670)
Current	(3,013)	(1,586)
Non-current	–	(84)
	<u>67,067</u>	<u>57,117</u>

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	June 30, 2021	December 31, 2020
	<i>US\$'000</i>	<i>US\$'000</i>
	<i>(Unaudited)</i>	<i>(Audited)</i>
Within 1 month	15,904	14,973
1 to 2 months	8,910	8,872
2 to 3 months	6,861	4,109
Over 3 months	35,392	29,163
	<u>67,067</u>	<u>57,117</u>

11. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of reporting period, based on the invoice date, is as follows:

	June 30, 2021	December 31, 2020
	<i>US\$'000</i>	<i>US\$'000</i>
	<i>(Unaudited)</i>	<i>(Audited)</i>
Within 1 month	7,726	4,100
1 to 2 months	4,936	3,358
2 to 3 months	681	1,865
Over 3 months	28	121
	<u>13,371</u>	<u>9,444</u>

12. EVENTS AFTER THE REPORTING PERIOD

Acquisition of Shanghai Foshion Medical System Co., Ltd.

On July 13, 2021, Sisram Medical (Tianjin) Limited (“**Sisram Tianjin**”), a wholly-owned subsidiary of the Company, acquired 100% equity interest of Shanghai Foshion Medical System Co., Ltd., from Fosun Pharmaceutical (Group) Co., Ltd. (“**Fosun Pharma**”) and Qianda (Tianjin) International Trading Co., Ltd, another wholly-owned subsidiary of Fosun Pharma. The total consideration for the acquisition is RMB312.4 million. Upon the completion, Shanghai Foshion Medical System Co., Ltd. became a wholly-owned subsidiary of the Company.

Sublicence agreement with Fosun Industrial

On July 14, 2021, Sisram Tianjin entered into a Sublicence Agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (“**Fosun Industrial**”), a wholly-owned subsidiary of Fosun Pharma, pursuant to which Sisram Tianjin agreed to sublicense from Fosun Industrial the relevant knowhows and patents of the finished form of the injectable pharmaceutical drug product (“**Licensed Product**”), so as to, among other things, import, use, sell or commercialize the Licensed Product in the PRC, Hong Kong SAR and Macau Special Administrative Region.

Placing of new shares

On July 27, 2021, a total of 24,000,000 new shares (“**Placing Shares**”), representing approximately 5.15% of the total issued share capital of the Company as enlarged by the allotment and issue of the Placing Shares, have been placed to no less than six Placees. The number of total issued shares of the Company has increased from 442,155,600 Shares to 466,155,600 Shares as a result of the issue of the Placing Shares.

MANAGEMENT DISCUSSION AND ANALYSIS

1. BUSINESS REVIEW

The Company is a leading global provider of energy-based medical aesthetic treatment systems, with comprehensive in-house capability to design, develop and produce such systems, which feature its innovative and proprietary technologies. Alma, the Company's core subsidiary, is also engaged in the injectables market with a distribution agreement from IBSA Derma ("**IBSA Derma**"), a Swiss cosmeceutical company and a leading subsidiary of IBSA Pharma Corporation, for the distribution of its products in Israel, Hong Kong Special Administrative Region ("**Hong Kong SAR**"), India and Mainland China. The "Alma" brand, as well as the brands of many of the Group's products such as "Soprano", "Harmony", "ClearLift", "Accent", "FemiLift" and "BeautiFill" are widely recognized and well regarded among treatment providers and treatment recipients worldwide. The Group also sells its treatment systems via distributors and direct sales customers in over 90 countries and jurisdictions worldwide.

The treatment systems developed and manufactured by the Company can be used for a broad range of non-invasive and minimally invasive medical aesthetic treatments. The Company has a comprehensive portfolio of treatment systems, including its medical aesthetic product line, which can be utilized to perform non-invasive medical aesthetic treatments such as hair removal, skin rejuvenation, skin resurfacing, body contouring, skin tightening, treatment of vascular and pigmented lesions, tattoo removal, acne treatment and cellulite reduction. The Company's treatment systems can also be utilized to perform minimally invasive treatments such as laser assisted liposuction and fat grafting, feminine health, treatment of varicose veins and ear, nose and throat procedures. The Company's flagship offerings include: (i) the "Soprano" family, primarily used for laser hair removal; (ii) the "Harmony" family, a versatile multi-application platform that can be used to treat more than 65 different Food and Drug Administration of the United States ("**FDA**") cleared indications; (iii) the "Accent" family, primarily used for body contouring and skin tightening, all of which belong to its medical aesthetic product line; (iv) "FemiLift", a minimally invasive treatment system for various feminine conditions; and (v) "BeautiFill" by LipoFlow platform, the first and only energy-based device cleared by the FDA for autologous fat grafting.

2. BUSINESS REVIEW OF FIRST HALF OF 2021

In the first half of 2021, Sisram's established global sales and distribution network recorded a total revenue of US\$125.3 million for the Reporting Period, representing an increase of 74.7% when compared to the corresponding period in 2020. The increase is primarily attributable to the Group's resilience and long-term planning throughout 2020, amidst the COVID-19 pandemic. As a veteran group with a robust financial backbone, we tapped into our cash for the ongoing business operation.

This enables us to maintain our human capital almost intact and sustain our operational resilience, while addressing our leading goals.

Profit for the period attributable to owners of the parent was US\$16.4 million, which represent 13.1% of revenue for the Reporting Period. Such percentage increased by 5.4% as compared to that for the corresponding period in 2020.

During the Reporting Period, gross profit of the Group amounted to US\$71.5 million compared to US\$39.9 million for the corresponding period in 2020, representing an increase of 79.1%. The gross profit margin increased to 57.0% for the Reporting Period from 55.6% for the corresponding period in 2020, primarily due to a higher revenue to overhead costs ratio. The establishment of direct operation offices in chosen territories has enabled the Company to shorten the supply chain and gain a higher brand visibility based on its highly valuable products. With this methodology in place, revenue derived from direct sales amounted to 59.7% of total revenue versus 40.3% of the total revenue attributed to sales via distributors.

During the Reporting Period, the Group recorded profit before tax of US\$20.1 million and recorded profit for the period of US\$17.4 million, representing an increase of 214.9% and 202.6% respectively, when compared to the corresponding period in 2020. The increase in profit before tax and profit for the period was mainly due to an increase in revenue (US\$53.6 million) and an increase in gross profit (US\$31.6 million).

During the Reporting Period, the Group recorded an adjusted net profit of US\$19.6 million representing an increase of 126.2% when compared with the corresponding period of 2020. The adjusted net profit margin for the Reporting Period was 15.6%. The increase in the adjusted net profit is mainly attributable to the increase in gross profit margin and the decrease in operating expenses.

The Company's business fundamentals are healthy. The Company has sufficient funds to meet its future business needs and sustain its operational resilience, while addressing the following leading goals:

1. Support employees and business partners during challenging times.
2. Adjust ongoing operation scope based on markets dynamics while balancing all necessary elements (sales, production, distribution, service, etc.).
3. Continue investments in strategic projects – upgrading IT infrastructures (ERP and CRM), new campus, R&D projects, clinical studies, business development, etc.
4. Protect financial assets and Company's value.
5. Growing our ecosystem of varied business lines and consumer brand, fulfilling the Group's long-term strategy.

R&D

- R&D investments increased by 62.5% to US\$8.1 million, compared to US\$5.0 million in the corresponding period in 2020.
- 14% of corporate employees are R&D specialists.
- During the Reporting Period, the Company launched 2 new products
 - “Alma Duo” – an in-office, aesthetic treatment that uses gold standard shock wave technology, focused low-intensity extracorporeal shock wave therapy (LI-ESWT), clinically validated to stimulate better blood flow and restore natural sexual performance; and
 - “Alma PrimeX” – a non-invasive body contouring platform, achieving unparalleled results in reducing circumference and skin tightening in using 3 proprietary technologies.
- On the clinical research front, the Group has conducted 29 clinical and preclinical studies (including sponsored and investigator sponsored trials) during the Reporting Period, in the aesthetics, dermatology, plastic surgery, and gynecology fields.
- Five clinical & pre-clinical studies are intended to support FDA clearances submissions for additional clinical indications and treatment platforms.

Sales and Marketing

As a multi-national operation, Sisram is required to adjust its sales and operating method according to each country/state limitations (such as USA, DACH and India, etc). This practice of global outlook with local focus that we call Glocalization methodology has been fully exploited during the Reporting Period to (1) monitor the pandemic situation in each country, (2) plan the recovery plan, and (3) coordinate across all subsidiaries and execute the plan.

Adjusting to the new market dynamics, we have performed the following activities:

- Upgrade to webinars activities as a substitute to cancelled face-to-face conferences, trainings and sales meetings. The Group has successfully conducted its second global online product launch, and unveiling Alma PrimeX platform. The launch was broadcasted from the Company's headquarter to five continents across multiple communication channels including YouTube.
- Launch multiple online campaigns to generate B2B and B2C leads across different territories.
- Increase content creation and social media presence to keep B2B and B2C dialogue going. Develop new social media channels to promote our brand globally, including a new TikTok account driving consumer awareness to Alma's brand.
- Conduct weekly video meetings with all distributors to ensure that we support our customers with solid answers, fast service, and positive reactions.

Mergers & Acquisition (“M&A”)

Foshion Acquisition

On April 22, 2021, Sisram Tianjin, Fosun Pharma and Qianda (Tianjin) International Trading Co., Ltd. entered into the sale and purchase agreement to acquire the entire issued share capital of Shanghai Foshion Medical System Co., Ltd. (“**Foshion**”) in consideration of RMB312.4 million (the “**Foshion Acquisition**”). Foshion is primarily engaged in the import and distribution of overseas dental equipment in the PRC.

On June 30, 2021, the independent shareholders of the Company approved the Foshion Acquisition, and the completion of the Foshion Acquisition took place on July 13, 2021. Please refer to the circular of the Company dated May 25, 2021 and the announcement dated July 13, 2021 for further information.

Nova Call Option Exercise

On July 29, 2021, Alma, the operating subsidiary of the Company, exercised the call option, pursuant to the share purchase agreement between Alma, Mr Ofer Gerassi, Mrs. Sabina Biran, Mr. Jacob Sayef Aaron and Nova dated November 16, 2018 to purchase the remaining 40% equity interest from Mr. Gerassi in Nova. Upon completion, Nova will become a wholly-owned subsidiary of the Company. Please refer to the announcement of the Company dated July 29, 2021 for further information.

Business Development

Sub-license Agreement

On July 14, 2021, Sisram Tianjin entered into the sublicense agreement with Fosun Industrial, a subsidiary of Fosun Pharma pursuant to which Sisram Tianjin agreed to sublicense from Fosun Industrial the relevant know-hows and patents of Licensed Product, so as to, among other things, import, use, sell or commercialize the Licensed Product in the PRC, Hong Kong SAR and Macau Special Administrative Region. The Licensed Product is an investigational product and the first neuromodulator with long-acting duration. It is a novel, next-generation neuromodulator in development for the treatment of aesthetic indications and a number of potential therapeutic conditions. Please refer to the announcement of the Company dated July 14, 2021 for further information.

Asia-Pacific (“APAC”) Focus

- During the Reporting Period, we have continuously explored new business opportunities, following the charted guidelines – strengthen our APAC position, diverse our business and create synergistic value with Alma.

Revenue derived from the APAC region increased by 54.9% in comparison to the corresponding period in 2020, accounting for 26.9% of the Group’s total revenue. Foreseeing big growth potential of the Chinese Medical Aesthetics market, the Company has a dedicated team to identify the sales approach accurately and meet the needs of end customers.

Operations

On the operations front, we have focused on the following:

- Addressing the pandemic effect
 - Enhance inbound materials visibility in response to decline in suppliers “on time delivery” performances.
 - Evaluate and exercise alternative outbound logistics options to deal with reduced airlines availability.
 - Provide required IT tools to allow employees to work from home when applicable.

- Continuous quality improvement across the global supply chain.
- Competitive procurement project, including advanced supply control structural methods, has been designed and is in implementation process.
- Alma’s new campus project has been completed and transition was done during August 2020. The campus functional design is based on ‘LEAN’ manufacturing methodology to ensure smooth and efficient material flow for the production floor.
- Digital and Information Technology (“IT”):
 - During the Reporting Period, Sisram invested US\$1.22 million in IT infrastructure upgrade. This ongoing significant investment is dating back to the beginning of 2019 and is planned to continue throughout 2022.
 - During the Reporting Period, Sisram continued the implementation of ERP system and rollouts across its subsidiaries.

3. OUTLOOK FOR SECOND HALF OF 2021

In the second half of 2021, Sisram intends to follow its constructive revolutionary strategy by evaluating and implementing near-future technologies, ventures, and synergies so as to bolster its global position. The Group’s efforts throughout 2021 will strategically focus on lean innovation, digitalization, brand and eco-system building.

The Group plans to expand its digital transformation strategy with the following major objectives:

- Adopt a customers’ centric operation mindset where activities are based on customer data, to facilitate informed decisions making corporate process.
- Digitize existing procedures, create new ones and centralize data.
 - Design Sisram’s digital core structure – a comprehensive set of digital solutions and tools that will enable Sisram to perform comprehensive business activity on its digital system. The digital functions will include e-commerce, customers portals, digital marketing, academic research, customer services, Business Intelligence, Internet of Things and more.
 - Design a growing, cumulative, shared customers and consumers database.

The Group will adhere its mission to provide modular, cost-effective and high-performance systems based on the very latest clinical research and cutting-edge technologies, fulfilling the corporate vision of “Enhancing Quality of Life”.

Strategic branding & positioning:

- Following a strategic brand positioning, the Group is now entering the implementation phase to combine the existing global brand influence with Sisram's new brand and global positioning to make Sisram an unique corporate in the wellness industry.
- For Alma's global positioning, we are exploring a worldwide renown presenter to become our brand spokesperson.

In addition, we plan to:

- 3.1. Complete the reconstruction of Sisram's organization structure and operation according to the charted vision of becoming the leading medical aesthetics care organization, providing premium care to our customers, using professional, on-time, quality services to maximize customers' value and loyalty and enhance the Group's business growth.
- 3.2. Focus R&D operation on next generation platforms in the areas of pre-juvenation, regenerative medicine and combined technologies.
- 3.3. Continue ongoing clinical studies, in addition to new studies aimed to support regulatory requirements (i.e., FDA study for additional clinical indications).
- 3.4. Continue to expand our Internet of Things service module with Cloud base application for smart clinic management in cooperation with high-end Internet of Things operators in China and North America.
- 3.5. Complete IBSA Derma products registration in China and expand the Israel, Hong Kong SAR and India injectables business by introducing additional products in this category.
- 3.6. Further develop our market share in direct operation territories.
- 3.7. Explore unexploited direct operation opportunities worldwide.
- 3.8. Distribute affiliating products and technologies in a private label/ODM model.
- 3.9. Leverage Fosun Pharma's resources in China to capture a larger market share (for surgical, injectables and cosmeceuticals segments).
- 3.10. Follow our eco-system strategic planning by searching, evaluating, and executing relevant M&A's initiatives that will further strengthen our R&D capabilities, products portfolio and distribution channels.

- 3.11. Expand the Group's presence and business in China via the new official Sisram's China office. The China office will handle various business activities addressing the evolving ecosystem and potential synergies between Sisram and its majority shareholder, Fosun Pharma. Amongst the first activities the new office oversees are: aesthetic dentistry, registration of dermal facial fillers, expansion of the injectables category offering, marketing development of personal care product and the establishment of a regional service center and regional warehouse.

4. FINANCIAL REVIEW

During the Reporting Period, the unaudited interim results and the summary of financial results are as follows:

A. Revenue

During the Reporting Period, revenue of the Group increased from US\$71.7 million to US\$125.3 million, representing an increase of 74.7% when compared to the corresponding period in 2020. The overall increase was primarily attributable to a significant increase in the sales volume of main consoles and applicators for the Company's different products, following the global economy recovery post initial COVID-19 impact. As of the date of this announcement, the clinical operation of medical aesthetics practices across the world has recovered almost close to its normal level prior to the outbreak of COVID-19.

Revenue by main product segments

The Group generates revenue from the following revenue streams: (i) sale of goods; and (ii) services and others. The revenue from sale of goods amounted to US\$118.1 million, representing an increase of 75.5% as compared to the corresponding period in 2020. The revenue from service and others amounted to US\$7.2 million, representing an increase of 62.7% as compared to the corresponding period in 2020.

The following table sets forth our revenue breakdown by main product lines and as a percentage of our total revenue for the six-month ended in the years indicated:

	Six months ended June 30				YOY %
	2021		2020		
	<i>(US\$ in thousands, except for percentages)</i>				
Sale of Goods:					
Medical Aesthetics	98,040	78.2%	55,985	78.0%	75.1%
Minimally invasive	17,137	13.7%	9,405	13.1%	82.2%
Injectables	2,873	2.3%	1,894	2.6%	51.7%
Subtotal	118,050	94.2%	67,284	93.7%	75.5%
Services and Others	7,243	5.8%	4,452	6.3%	62.7%
Total	125,293	100.0%	71,736	100.0%	74.7%

We have derived a substantial majority of our revenue from our Medical Aesthetics product line, representing 78.2% of our total revenue for the Reporting Period. Revenue from the sale of our Medical Aesthetics line was US\$98.0 million for the six months ended June 30, 2021, representing an increase of 75.1% in comparison with a revenue of US\$56.0 million in the corresponding period in 2020. The majority of revenue derived from our leading platforms such as “Soprano”, “Harmony”, “Opus” and “Accent”.

Revenue from our Minimally invasive product line increased by 82.2% and amounted to US\$17.1 million compared to US\$9.4 million for the corresponding period in 2020. The increased is mainly attributed to the launch of Alma Duo in North America, accounting for US\$5.3 million for the Reporting Period. Alma Duo is an in-office, aesthetic treatment that uses gold standard shock wave technology, focused low-intensity extracorporeal shock wave therapy (LI-ESWT), clinically validated to stimulate better blood flow and restore natural sexual ability.

Revenue by geographic segments

The following table sets forth our revenue by geographic segments for the six months ended in the years indicated (measured by the location of our direct sales customers and our distributors):

	Six months ended June 30				YOY %
	2021		2020		
	<i>(US\$ in thousands, except for percentages)</i>				
Europe	23,698	18.9%	16,367	22.8%	44.8%
North America	49,147	39.2%	22,848	31.9%	115.1%
APAC	33,744	26.9%	21,779	30.4%	54.9%
Middle East and Africa	12,636	10.2%	7,581	10.5%	66.7%
Latin America	6,068	4.8%	3,161	4.4%	92.0%
Total	<u>125,293</u>	<u>100.0%</u>	<u>71,736</u>	<u>100.0%</u>	<u>74.7%</u>

During the Reporting Period, North America, APAC, and Europe were the Company’s most important geographic segments by revenue contribution, though sales were distributed broadly across many regions globally. The Company has strived to maintain and expand its geographically diverse sales network, which will allow the Company to readily capture strong regional demand, as well as help the Company to balance and minimise risks from regional economics downfalls.

The revenue derived from North America accounted for US\$49.1 million during the Reporting Period, an increase of 115.1% from US\$22.8 million for the corresponding period in 2020. The increase is attributed to the strong position of Alma's brand in North America, following the continuous growing investments in sales and marketing operation including the recruitment of sales professionals to enhance the sales team capacity. Our strong marketing, branding and sales promotions for the Alma Duo and Alma Opus platforms resulted in a highly successful launch and commercialization of these platforms.

The revenue derived from APAC increased by 54.9% to US\$33.7 million in the Reporting Period from US\$21.8 million for the corresponding period in 2020. The increase is mainly attributed to our strong performance in China, Japan and our Australian direct operation. The APAC revenue growth is mainly attributed to such region's recovery from COVID-19, leading to an increase in demand, mainly for Alma's Thermolift, Harmony and LipoLife treatments.

The revenue derived from Europe increased by 44.8% to US\$23.7 million in the Reporting Period from US\$16.4 million for the corresponding period in 2020. The increase is mainly attributed to the continued momentum of our strong hair removal brand “Soprano”, as well as strong distribution channel in Italy and Spain, despite the challenging pandemic situation.

The revenue derived from Middle East and Africa increased by 66.7% to US\$12.6 million in the Reporting Period from US\$7.6 million for the corresponding period in 2020. The increase is mainly attributed to the recent increasing efforts in Israeli direct operation.

The revenue derived from Latin America increased by 92.0% to US\$6.1 million in the Reporting Period from US\$3.2 million for the corresponding period in 2020. The increase is due to our strong distribution channel in Argentina, Brazil, Chile and Mexico.

During the Reporting Period, the cost of sales primarily comprised of the costs of production materials, and to a lesser extent, remuneration of production employees, the cost of rendering of services, and overheads and other miscellaneous costs relating to production. For the Reporting Period, the cost of sales of the Group increased by 69.0% to US\$53.8 million from US\$31.8 million for the corresponding period in 2020, which is mainly due to increase in sales volume.

B. Gross profit and gross profit margin

During the Reporting Period, gross profit of the Group increased by 79.1% to US\$71.5 million from US\$39.9 million for the corresponding period in 2020 for the reasons set out in Revenue and Cost of sales above.

The gross profit margin increased to 57% for the Reporting Period from 55.6% for the corresponding period in 2020. The increase is primarily attributed to a higher revenue to overhead costs ratio.

C. Selling and distribution expenses

The selling and distribution expenses primarily consist of: (i) employees’ salaries and related cost; (ii) sales commission to sales employees and independent agents; (iii) marketing expenses such as participation in tradeshows and digital activities.

During the Reporting Period, selling and distribution expenses of the Group increased by 51.4% to US\$30 million from US\$19.8 million for the corresponding period in 2020, the increase is resulted from new sales positions worldwide compared to the corresponding period in 2020, higher commission expenses following the increase in sales volume, mainly in the North America operation, and increase in marketing expenses.

D. Administrative expenses

Administrative expenses primarily consist of: (i) amortization of intangible assets; (ii) remuneration paid to administration employees; (iii) professional fees paid and administrative costs; (iv) fees relating to the operation facilities; and (v) other miscellaneous expenses.

During the Reporting Period, administrative expenses of the Group increased by 14.7% to US\$9.3 million from US\$8.1 million for the corresponding period in 2020. The increase is mainly attributed to IT manpower investments for the new ERP, service, HR and corporate systems implementation and support.

Administrative expenses also include amortization of intangible assets arising from the acquisitions of Alma and Nova. During the Reporting Period, the amortization expense amounted to US\$2.5 million, a decrease from US\$3.1 million in the corresponding period in 2020.

E. R&D

The Group's R&D expenses primarily consist of: (i) remuneration to R&D team members; (ii) cost of materials used in R&D efforts; (iii) expenses related to clinical studies; and (iv) expenses related to regulatory compliance and registration of patents and trademarks. During the Reporting Period, majority of R&D expenses were recorded in the period that such expenses were incurred and were not capitalized.

During the Reporting Period, R&D expenses increased by 62.5% to US\$8.1 million from US\$5.0 million for the corresponding period in 2020.

F. Finance costs

Finance costs are comprised mainly of (i) interest on bank loans and (ii) interest on lease liabilities. Finance costs increased to US\$0.9 million in the Reporting Period from US\$0.3 million for the corresponding period in 2020, since lower interests are recorded on debts during the Reporting Period due to the repayment of bank loans.

G. Income tax expense

The Israeli corporate tax rates are both 23% in 2020 and 2021. Each entity in the Group is taxable based on its standalone results as measured by the local tax system.

During the Reporting Period, income tax expense increased to US\$2.8 million, representing an increase of 322.9% from US\$0.7 million for the corresponding period in 2020. This was primarily attributable to the higher income before tax. In addition, Alma enjoyed special taxation terms from January 1, 2017.

On December 4, 2018 a ruling from the Israeli Income Tax Authority granted Alma a SPTE status, in accordance with the legal criteria and the conditions mentioned in the ruling, effective from January 1, 2017.

H. Profit for the period

As a result of the foregoing, during the Reporting Period, our profit for the period increased by 202.6% to US\$17.4 million from US\$5.7 million for the corresponding period in 2020. The net profit margin of the Group for the six months ended in June 30, 2021 and 2020 were 13.9% and 8.0%, respectively.

I. Adjusted net profit and adjusted net profit margin

The Group calculates adjusted net profit by taking profit for the period and adjusting: (i) amortization of other intangible assets; (ii) changes in contingent consideration arising from the acquisition of Nova; and (iii) deferred tax liability arising from other intangible assets, which primarily relates acquisitions. The Group calculates adjusted net profit margin by dividing adjusted net profit by revenue.

The Group presents this financial measure because it is used to evaluate financial performance by excluding the impact of items that the Group does not consider indicative of the Group's ordinary operating performance.

The term adjusted net profit is not a financial measure defined under IFRSs. The use of adjusted net profit has material limitations as an analytical tool, as it does not include all items that impact net profit for the period. Items excluded from adjusted net profit are significant components in understanding and assessing the Group's operating and financial performance. The following table reconciles the adjusted net profit for the Reporting Period presented to the most directly comparable financial measure calculated and presented in accordance with IFRSs, which is profit for the period:

	Six months ended June 30		
	2021	2020	YOY%
	<i>US\$'000</i>	<i>US\$'000</i>	
PROFIT FOR THE PERIOD	<u>17,361</u>	<u>5,738</u>	<u>202.6%</u>
Adjusted for:			
Amortization of other intangible assets arising from the Alma acquisitions	2,305	2,305	-%
Amortization of other intangible assets arising from the Nova acquisitions	239	812	(70.6)%
Contingent consideration arising from acquisitions	(9)	262	(103.4)%
Deduct: deferred tax arising from other intangible assets	<u>(339)</u>	<u>(471)</u>	<u>(28)%</u>
Adjusted net profit	<u>19,557</u>	<u>8,646</u>	<u>126.2%</u>
Adjusted net profit margin	<u>15.6%</u>	<u>12.1%</u>	

5. DEBT STRUCTURE, LIQUIDITY AND SOURCES OF FUNDS

A. Treasury policy

The Board aims to have a better control in its treasury operations and endeavors to maintain an adequate level of cash and cash equivalents. The functional currency of the Group is the U.S. Dollar and most of the sales proceeds are denominated in U.S. Dollar. Please see “Risk Management – Foreign Currency Exposure” for further details. The Group generally finances its operation with internally generated resources.

To ensure that the financial resources have been used in the most cost-effective and efficient way, the Board would also consider various funding sources to address the Group’s financial obligations and operational needs. The Board would also review and evaluate the adequacy and effectiveness of the treasury functions from time to time.

B. Gearing ratio

As at June 30, 2021 and June 30, 2020, the Group’s cash and cash equivalents exceeded the total debt. As such, no gearing ratio was presented.

C. Interest coverage

During the Reporting Period, the interest coverage, which is calculated by EBIT (Earnings Before Interest and Taxes) divided by financial costs was 22.9 times as compared with 19.4 times for the corresponding period in 2020. The interest coverage increased mainly because the Group’s EBIT during the Reporting Period increased by 212% to US\$21.1 million from US\$6.7 million for the corresponding period in 2020, and finance cost increased by 165.1% to US\$0.9 million from US\$0.3 million for the corresponding period in 2020.

D. Available facilities

As at June 30, 2021, Sisram did not have any unutilized banking facilities. Sisram is mainly financing its operations through cash generated from operating activities.

E. Interest rate

As at June 30, 2021, total interest-bearing bank and other borrowings at a fixed interest rate amounted to US\$0.4 million (As at December 31, 2020: US\$1.7 million).

F. Maturity structure of outstanding debts

The following table sets forth the maturity structure of outstanding debts as at June 30, 2021 and December 31, 2020.

	June 30, 2021			December 31, 2020		
	Effective interest rate (%)	Maturity	US\$'000	Effective interest rate (%)	Maturity	US\$'000
Current						
Short-Term Bank Credit	3.56	2021	264	3.25-3.65	2021	1,134
Current portion of long-term bank loans, secured	3.56	2021	<u>84</u>	3.1-3.8	2021	<u>384</u>
			348			1,518
Non-current						
Bank loan, secured	3.56	2022	<u>58</u>	3.1-3.8	2022	<u>180</u>
			<u>406</u>			<u>1,698</u>
				June 30, 2021	December 31, 2020	
				US\$ '000	US\$ '000	
Within 1 year				348	1,518	
1 to 2 years				<u>58</u>	<u>180</u>	
Total				<u>406</u>	<u>1,698</u>	

G. Collateral and pledged assets

Nova, Alma's subsidiary, entered into a loan agreement, pursuant to which Nova pledged to the banks all of the issued and outstanding shares of Nova and a floating charge over all of the present and future assets of Nova as they may be from time to time. The remaining balance of such loan amounted to US\$0.3 million as at June 30, 2021.

6. CASH FLOW

Sisram is using its cash primarily for its operating activities, payments of interest and principals of debts due, payments for purchases and capital expenditures and funding growth and expansion of its business.

The table below shows the cash flow of the Group generated from (or used in) operating activities, investing activities and financing activities for the Reporting Period and the corresponding period of 2020.

	Six months ended June 30		YOY%
	2021 US\$'000	2020 US\$'000	
Net cash flows from/(used in) operating activities	20,834	(110)	18,980%
Net cash flows (used in)/from investing activities	(9,752)	2,360	(513.2)%
Net cash flows used in financing activities	<u>(3,464)</u>	<u>(3,150)</u>	<u>10.0%</u>
Net increase/(decrease) in cash and cash equivalents	7,618	(900)	946.4%
Cash and cash equivalents at the beginning of the period	83,373	99,735	(16.4)%
Effect of foreign exchange rate changes, net	<u>(1,710)</u>	<u>152</u>	<u>(1,225.0)%</u>
Cash and cash equivalents at the end of the period	<u><u>89,281</u></u>	<u><u>98,987</u></u>	<u><u>(9.8)%</u></u>
Cash and cash equivalents			
Pledged bank balances for long term bank loans	149	84	77.4%
Term deposits with original maturity of more than three months	<u>40,000</u>	<u>–</u>	<u>–%</u>
Cash and bank balance at the end of the period	<u><u>129,430</u></u>	<u><u>99,071</u></u>	<u><u>30.6%</u></u>

Net cash flows from operating activities

During the Reporting Period, the net cash flows provided by operating activities were US\$20.8 million, which was primarily attributable to: (i) the profit before tax of US\$20.1 million; (ii) total adjustments for profit or loss items of US\$10.4 million; (iii) working capital adjustments of US\$7.6 million; and (iv) income tax paid, net of US\$2.1 million.

Net cash flows used in investing activities

During the Reporting Period, the net cash flows used in investing activities were US\$9.8 million, which was primarily attributable to: (i) short term bank deposits with the amount of US\$7.0 million, (ii) US\$0.2 million interest received from term deposits, (iii) US\$2.0 million in purchase of plant and equipment and (iv) investment in an associate in the amount of US\$1.0 million.

Net cash flows used in financing activities

During the Reporting Period, the net cash flows used in financing activities was US\$3.5 million, which was primarily attributable to: (i) repayments on loan and interest of US\$1.4 million; and (ii) payment of lease payments of US\$2.1 million.

7. CAPITAL COMMITMENTS AND CAPITAL EXPENDITURES

During the Reporting Period, capital expenditures of the Group amounted to US\$2.1 million, which mainly consisted of additions to the plant facility and ERP Costs.

As at June 30, 2021, the Group did not have any significant capital commitments.

On December 22, 2020, Sisram Tianjin, a subsidiary of the Company, entered into the series A investment agreement as an original shareholder and a series A investor with, among others, Fosun Health Fund (Suzhou) and Fosun Health Fund (Tianjin) (the general partners of which are subsidiaries of Fosun Pharma and Tianjin JuveStar Bio-technology Company Ltd (“**Tianjin JuveStar**”) in relation to an aggregate capital injection of US\$16,705,000 (equivalent to RMB109,000,000) into Tianjin JuveStar, to which, Sisram Tianjin agreed to contribute US\$1,533,000 (equivalent to RMB10,000,000). During the Reporting Period, the Group contributed US\$950,000 to Tianjin JuveStar. The remaining amount will be paid once the related payment conditions are satisfied.

8. CONTINGENT LIABILITIES

As at June 30, 2021, the Group did not have any contingent liabilities.

9. MATERIAL ACQUISITION AND DISPOSAL

Save as the Foshion Acquisition disclosed in “*Management Discussion & Analysis*” above, during the Reporting Period, the Group did not conduct material acquisition or disposal.

10. SIGNIFICANT INVESTMENTS HELD AND FUTURE PLANS FOR MATERIAL INVESTMENTS AND CAPITAL ASSETS

Save for those disclosed in this announcement, there were no other significant investments held as at June 30, 2021. The Group did not have other plans for material investments and capital assets.

11. RISK MANAGEMENT

The operation and development of the Group are not exposed to any material risk factors, but they will be impacted to a certain extent by several factors as illustrated below:

A. Foreign currency exposure

The functional currency of the Group is the U.S. Dollar and most of the sales proceeds are denominated in the U.S. Dollar. However, the Company also generates revenue globally in a few other currencies, particularly Euros, and incurs costs mostly in New Israeli Shekels. Furthermore, the functional currencies of certain subsidiaries are currencies other than the U.S. Dollar, including the Euros, the Indian Rupee, the New Israeli Shekels, the HK Dollar, the South Korean Won and the Australian Dollar. As at the end of the Reporting Period, the assets and liabilities of these entities were translated into the U.S. Dollar at the exchange rates prevailing at the end of the Reporting Period and their statements of profit or loss were translated into the U.S. Dollar at the weighted average exchange rates for the period. As such, the Group's results of operations are sensitive to changes in foreign currency exchange rates.

The Company has formally established a hedging management framework in 2014 and the hedging transactions are mainly managed by the Company's finance department. By analyzing the currency balance sheet and trends in the foreign exchange markets, the Company has entered into forward contracts from time to time to mitigate the adverse effects of exchange rate fluctuations.

B. Interest rate exposure

It is the Group's strategy to use debts with fixed and floating interest rates to manage its interest costs. The Group's exposure to the risk of changes in market interest rates relates primarily to the Group's debt obligations with floating interest rates.

12. EMPLOYEES AND REMUNERATION POLICIES

The following table sets forth the number of employees by function as at June 30, 2021:

Function	Number of Employees
Operations	191
R&D	73
Sales & Marketing	204
General and Administration	70
Total	<u>538</u>

Employees' headcount as at the end of Reporting Period increased by 10.9% due to 53 new positions, as compared to the December 31, 2020.

The employees' remuneration includes basic salary and a performance-based bonus. The performance-based bonus is determined by reference to the performance appraisal of the employees of the Group. Through clearly locating position-oriented performance targets and formulating performance standards, the Company has managed to assess employees' performance in an objective manner. By materializing reward and penalty in the performance-related portion of the employees, the Company is able to achieve the coexistence of incentives and restraints.

13. USE OF PROCEEDS FROM THE GLOBAL OFFERING

Total net proceeds from the Global Offering amounted to HK\$771.3 million. As at the end of the Reporting Period, approximately HK\$359.60 million has been used in accordance with the plan disclosed in the Prospectus of the Company (as adjusted in accordance with the announcements issued by the Company on October 8, 2018 and April 22, 2021). As of the date of this Announcement, all such HK\$359.60 million of net proceeds have been used for the Fashion Acquisition, which was completed on July 13, 2021.

INTERIM DIVIDEND

The Board has resolved not to declare any interim dividend for the six months ended June 30, 2021.

PURCHASE, SALE AND REDEMPTION OF LISTED SECURITIES

During the Reporting Period, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities.

COMPLIANCE WITH CORPORATE GOVERNANCE CODE

The Company's corporate governance practices are based on the principles and code provisions set forth in the Corporate Governance Code and Corporate Governance Report (the "CG Code") contained in Appendix 14 to the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the "Listing Rules").

During the Reporting Period, the Company has complied with all applicable principles and code provisions of the CG Code.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted Directors' and Chief Executive Officer's Dealing Policy on terms no less exacting than the required standard under the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix 10 to the Listing Rules as its own code of conduct regarding directors' securities transactions. Having made specific enquiries to all of the directors of the Company, all directors of the Company confirmed that they have fully complied with the relevant requirements set out in its own code of conduct during the Reporting Period.

AUDIT COMMITTEE

The audit committee of the Company has reviewed the unaudited interim results of the Group for the six months ended June 30, 2021 prepared in accordance with IFRSs.

PUBLICATION OF INTERIM RESULTS AND 2021 INTERIM REPORT

This results announcement is published on the website of the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) at <http://www.hkexnews.hk> and on the website of the Company at <http://www.sisram-medical.com>. The 2021 interim report containing all the information required by the Listing Rules will be dispatched to the shareholders of the Company in due course and will be published on the websites of the Company and the Stock Exchange.

APPRECIATION

The Group would like to express its appreciation to all the staff for their outstanding contribution towards the Group’s development. The Board wishes to sincerely thank the management for their dedication and diligence, which are key factors for the Group to continue its success in future. Also, the Group wishes to extend its gratitude for the continued support from its shareholders, customers, and business partners. The Group will continue to deliver sustainable business development, so as to create more values for all its shareholders.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Yi LIU
Chairman

Hong Kong, August 22, 2021

As at the date of this announcement, the Board of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as executive directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Rongli FENG as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

* *For identification purpose only*